证券代码：688382 证券简称：益方生物 公告编号：2025-038 益方生物科技（上海）股份有限公司 关于诉讼事项进展的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 近日，公司收到上海市高级人民法院《民事判决书》（案号：（2024）沪民 终 679 号）。米拉蒂公司因与公司、美国益方及 XING DAI（代星）侵害技术秘 密纠纷一案，不服上海知识产权法院作出的（2022）沪 73 知民初 1130 号民事 案件所处的诉讼阶段：二审判决 公司所处的当事人地位：益方生物科技（上海）股份有限公司（以下 简 称 " 公 司 " ） 及 全 资 子 公 司 益 方 生 物 科 技 有 限 责 任 公 司 （INVENTISBIO LLC.，以下简称"美国益方"）为一审被告，二审被 上诉人 涉案的金额：米拉蒂医疗股份有限公司（MIRATI THERAPEUTICS, INC.，以下简称"米拉蒂公司"）请求法院撤销一审判决，并判令公 司、美国益方及 XING DAI（代星）停止侵权行为，判令公司及美国益 方停 ...

Core Viewpoint - Next week, 36 stocks will face a lock-up expiration, with a total market value of 40.081 billion yuan set to be released [2][3]. Group 1: Lock-up Expiration Details - A total of 36 stocks will have their lock-up period expire over the next two trading days, amounting to a combined market value of 40.081 billion yuan based on the latest closing prices [2]. - Ningbo Port will see 3.647 billion shares become tradable, primarily from a directed placement, with a lock-up value of 13.202 billion yuan [3]. - Wan Kai New Materials will have 230 million shares released, mainly from original shareholders, with a lock-up value of 4.665 billion yuan [3]. - Eight stocks, including Changhong Energy and Lanzhou Bank, will have relatively low lock-up pressures, with values under 10 million yuan [3]. Group 2: Performance of Stocks Facing Expiration - Among the 36 stocks, 7 reported losses in the first half of the year, with companies like Woge Optoelectronics and Andar Intelligent showing significant losses exceeding 50 million yuan [5]. - The average stock price of the 36 stocks has increased by 0.64% since September, with Weiteou and Tonglian Precision showing the highest gains of 59.4% and 41.67%, respectively [4]. - Stocks that have seen price declines include Guangzi International and Aike Saibo, with Yifang Bio-U experiencing the largest drop of 18.31% since September [4]. Group 3: Institutional Research and Market Sentiment - Eight stocks facing lock-up expiration have received institutional research in the past month, indicating interest from institutional investors [4]. - Xidi Micro has garnered attention from 51 institutional investors, focusing on a diversified product matrix in consumer electronics and extending into automotive and industrial sectors [4]. - Jiao Cheng Ultrasonic has been researched by 36 institutions, highlighting its comprehensive ultrasonic solutions in the power semiconductor field and established partnerships with notable companies [4].

Company Overview - Yifang Biotechnology (Shanghai) Co., Ltd. is located in the China (Shanghai) Free Trade Zone and was established on January 11, 2013. The company went public on July 25, 2022. Its main business involves the research, production, and sales of innovative drugs, with 100% of its revenue coming from technology licensing and cooperation [1]. Stock Performance - On September 26, Yifang Biotechnology's stock fell by 5.09%, trading at 31.70 CNY per share, with a transaction volume of 134 million CNY and a turnover rate of 1.00%. The company's total market capitalization is 18.333 billion CNY [1]. Fund Holdings - According to data from major funds, Guolian Fund has a significant holding in Yifang Biotechnology. The Guolian Medical Consumption Mixed A Fund (015032) reduced its holdings by 71,100 shares in the second quarter, retaining 152,100 shares, which accounts for 5.93% of the fund's net value, making it the third-largest holding. The estimated floating loss today is approximately 258,600 CNY [2]. Fund Performance - The Guolian Medical Consumption Mixed A Fund (015032) was established on March 9, 2022, with a latest scale of 33.0955 million CNY. Year-to-date, it has achieved a return of 57.31%, ranking 816 out of 8,171 in its category. Over the past year, it has returned 82.14%, ranking 1,091 out of 8,004. Since inception, the fund has returned 11.96% [2]. Fund Management - The fund manager of Guolian Medical Consumption Mixed A Fund (015032) is Pan Tianqi, who has been in the position for 5 years and 178 days. The total asset size of the fund is 84.1388 million CNY, with the best return during his tenure being 8% and the worst being -0.27% [3].

Core Viewpoint - The A-share market is experiencing a significant rebound, particularly in the Sci-Tech Innovation Board, with the ETF Huatai-PineBridge (589120) showing a notable increase of 1.59% as of 13:54 on September 24, and attracting over 20 million yuan in net subscriptions within three trading days [1][3]. Group 1: ETF Performance - The Huatai-PineBridge Sci-Tech Innovation Drug ETF (589120) has seen strong performance, with most of its constituent stocks rising, including Teva Biopharma up over 3%, and several others like Zai Lab and Eucure Biopharma rising over 2% [3]. - The top ten constituent stocks of the ETF include notable companies such as RYSE Pharmaceuticals (688235) with a weight of 9.92% and a rise of 1.93%, and Eucure Biopharma (688578) with a weight of 8.03% and a rise of 2.27% [4]. Group 2: Market Dynamics - The National Healthcare Security Administration is set to hold a communication meeting in Beijing to discuss negotiations and pricing with companies, marking a significant innovation in this year's healthcare directory adjustments [5]. - The current innovation drug market is driven by the trend of "local innovation - global monetization," which is seen as a key support for the industry's growth [6]. - Analysts from Xinda Securities believe that the trend of innovation in the drug sector is not over, with expectations for continued growth in innovative drugs, medical devices, and AI healthcare [7]. Group 3: Industry Outlook - Tianfeng Securities highlights that the Chinese innovative drug industry has achieved significant results and is now globally competitive, entering a phase of self-sustainability through commercialization [8]. - The industry is supported by favorable policies, a well-structured talent pool, and a collaborative approach between academia and industry, which enhances the efficiency of drug development [9]. - The future outlook suggests that increasing innovation will further unlock commercial value, with China becoming one of the most efficient countries in the drug development process [10].

Core Viewpoint - Yifang Bio has experienced significant stock price fluctuations, with a year-to-date increase of 151.05%, but a recent decline over the past few trading days [1][2] Company Overview - Yifang Bio is located in the Shanghai Free Trade Zone and was established on January 11, 2013, with its IPO on July 25, 2022. The company focuses on the research, production, and sales of innovative drugs, with 100% of its main business revenue coming from technology licensing and cooperation [1] Financial Performance - For the first half of 2025, Yifang Bio reported revenue of 19.16 million yuan, a year-on-year increase of 28.85%. However, the net profit attributable to shareholders was -119 million yuan, reflecting a year-on-year increase of 44.25% in losses [2] Stock Market Activity - As of September 24, Yifang Bio's stock price was 33.39 yuan per share, with a market capitalization of 19.31 billion yuan. The stock has seen a trading volume of 120 million yuan and a turnover rate of 0.88% [1] - The company has appeared on the "Dragon and Tiger List" three times this year, with the most recent instance on July 11, where it recorded a net purchase of 68.87 million yuan [1] Shareholder Information - As of June 30, 2025, Yifang Bio had 9,790 shareholders, a decrease of 7.28% from the previous period. The average number of circulating shares per shareholder increased by 7.85% to 40,990 shares [2] - Notable institutional shareholders include Huatai-PB Innovation Medicine Mixed A and others, with significant changes in holdings among the top ten circulating shareholders [2]

Group 1 - Yifang Biotechnology's stock price fell by 5.04% on September 23, reaching 32.01 CNY per share, with a trading volume of 376 million CNY and a turnover rate of 2.69%, resulting in a total market capitalization of 18.512 billion CNY [1] - The company's stock has experienced a continuous decline for six days, with a cumulative drop of 7.59% during this period [1] - Yifang Biotechnology, established on January 11, 2013, and listed on July 25, 2022, focuses on the research, production, and sales of innovative drugs, with its main revenue source being technology licensing and cooperation, accounting for 100% of its revenue [1] Group 2 - Jin Ying Fund holds a significant position in Yifang Biotechnology, with its Jin Ying Medical Health Stock A fund (004040) owning 804,200 shares, representing 7.11% of the fund's net value, making it the second-largest holding [2] - The fund has incurred a floating loss of approximately 1.3671 million CNY today and a total floating loss of 2.2276 million CNY during the six-day decline [2] - Jin Ying Medical Health Stock A fund was established on August 1, 2017, with a current size of 140 million CNY, achieving a year-to-date return of 24.46% and a one-year return of 39.4% [2]

Group 1 - Yifang Biotechnology's stock price fell by 5.04% on September 23, closing at 32.01 yuan per share, with a trading volume of 376 million yuan and a turnover rate of 2.70%, resulting in a total market capitalization of 18.512 billion yuan [1] - The stock has experienced a continuous decline for six days, with a cumulative drop of 7.59% during this period [1] - Yifang Biotechnology, established on January 11, 2013, and listed on July 25, 2022, focuses on the research, production, and sales of innovative drugs, with 100% of its main business revenue derived from technology licensing and cooperation [1] Group 2 - Pengyang Fund holds a significant position in Yifang Biotechnology, with its Pengyang Medical Health Mixed A Fund (018052) owning 137,900 shares, accounting for 6.6% of the fund's net value, making it the second-largest holding [2] - The fund has incurred a floating loss of approximately 234,500 yuan today and a total floating loss of 382,100 yuan during the six-day decline [2] - The Pengyang Medical Health Mixed A Fund was established on October 31, 2023, with a latest scale of 22.571 million yuan, achieving a year-to-date return of 54.44% and a one-year return of 59.89% [2]

Core Points - The company, Yifang Bio, announced the results of the second vesting period for its 2022 restricted stock incentive plan [1] - The total number of shares available for circulation in this stock listing is 20,647 shares [1] - The stock listing date is set for September 29, 2025 [1] Summary by Category Stock Incentive Plan - Yifang Bio's stock listing type is classified as equity incentive shares [1] - The method of stock subscription is offline [1] Listing Details - The total number of shares for this stock listing is 20,647 [1] - The circulation date for the shares is September 29, 2025 [1]

益方生物科技（上海）股份有限公司 关于 2022 年限制性股票激励计划预留授予部分第二个 归属期归属结果暨股票上市公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 证券代码：688382 证券简称：益方生物 公告编号：2025-037 （三）2022 年 12 月 24 日至 2023 年 1 月 2 日，公司对本次激励计划首次授予 激励对象的姓名和职务在公司内部进行了公示。在公示期内，公司监事会未收到 与本次激励计划首次授予激励对象有关的任何异议。2023 年 1 月 3 日，公司于上 海证券交易所网站（www.sse.com.cn）披露了《益方生物监事会关于公司 2022 年 限制性股票激励计划首次授予激励对象名单的审核意见及公示情况说明》。 （四）2023 年 1 月 9 日，公司召开 2023 年第一次临时股东大会，审议并通过 了《关于<益方生物科技（上海）股份有限公司 2022 年限制性股票激励计划（草 案）>及其摘要的议案》《关于<益方生物科技（上海）股份有限公司 2022 年限制 性股票激励计划实施考核管 ...

9月19日，益方生物跌1.14%，截至发稿，报33.93元/股，成交3.51亿元，换手率2.46%，总市值196.23亿 元。益方生物股价已经连续5天下跌，区间累计跌幅6.99%。 责任编辑：小浪快报 国投瑞银上证科创板200指数发起式A（023518）成立日期2025年3月18日，最新规模7007.47万。成立以 来收益32.43%。 国投瑞银上证科创板200指数发起式A（023518）基金经理为赵建、钱瀚。 截至发稿，赵建累计任职时间11年362天，现任基金资产总规模38.48亿元，任职期间最佳基金回报 172.91%， 任职期间最差基金回报-88.73%。 钱瀚累计任职时间2年37天，现任基金资产总规模9.36亿元，任职期间最佳基金回报36.41%， 任职期间 最差基金回报1.33%。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 资料显示，益方生物科技(上海)股份有限公司位于中国(上海)自由贸易试验区李冰路67弄4号210室，成 立日期2013年1月11日，上市 ...